Overall survival (OS) with palbociclib (PAL) + fulvestrant (FUL) in women with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC): Updated analyses from PALOMA-3.

JOURNAL ARTICLE published 20 May 2021 in Journal of Clinical Oncology

Authors: Massimo Cristofanilli | Hope S. Rugo | Seock-Ah Im | Dennis J. Slamon | Nadia Harbeck | Igor Bondarenko | Norikazu Masuda | Marco Colleoni | Angela DeMichele | Sherene Loi | Hiroji Iwata | Ben O'Leary | Eustratios Bananis | Yuan Liu | Xin Huang | Sindy Kim | Mariajose Lechuga | Nicholas C. Turner